- Home
- MAKO vs ARDX Comparison
MAKO vs ARDX Comparison
Compare MAKO & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MAKO | ARDX |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | Canada | United States |
| Employees | 30 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 861.6M | 797.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | MAKO | ARDX |
|---|---|---|
| Price | $8.69 | $3.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $12.90 |
| AVG Volume (30 Days) | 101.2K | ★ 4.1M |
| Earning Date | 11-15-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | $76.73 | $19.98 |
| Revenue Next Year | $0.38 | $27.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.58 | $3.05 |
| 52 Week High | $11.10 | $8.40 |
Technical Indicators
Market Signals| Indicator | MAKO | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 39.39 | 37.64 |
| Support Level | $8.43 | N/A |
| Resistance Level | $10.64 | $3.63 |
| Average True Range (ATR) | 0.31 | 0.13 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 26.39 | 28.38 |
Price Performance
Historical ComparisonAbout MAKO Mako Mining Corp Common Stock
Mako Mining Corp is a gold mining, development, and exploration firm. The companies primary asset is the San Albino mine, an open-pit mine located in Nicaragua. In addition to its mining operation, the company continues to explore its other concessions in Nicaragua and Guyana.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.